Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROter: 177Lu-PSMA-R2 in mCRPC
NCT03490838Phase 1Terminated
- Sponsor
- Advanced Accelerator Applications
- Start
- May 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of lutetium lu-177 psma-r2 in metastatic castration-resistant prostate cancer (mCRPC) (6 cohorts), sponsored by Advanced Accelerator Applications. Primary endpoints: Incidence of dose limiting toxicities at 8 weeks and Prostate-Specific Antigen (PSA) response rate 50 at 13 weeks. Started May 2018; status: terminated.
02
Drugs
lutetium lu-177 psma-r2
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03490838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03490838.